NOVEL MODULATORS OF GABABR1a

Joris de Wit; Ana Rita Santos; João Carvalho; Laurent Galibert; Inge Van Molle; Han Remaut; Sylvain Celanire

NOVEL MODULATORS OF GABABR1a

Joris de Wit (Inventor), Ana Rita Santos (Inventor), João Carvalho (Inventor), Laurent Galibert (Inventor), Inge Van Molle (Inventor), Han Remaut (Inventor), Sylvain Celanire (Inventor)

Research output: Patent

Abstract

The present invention relates to the field of disorders of the central and peripheral nervous system, in particular neurological and psychiatric disorders, and the prevention and/or treatment thereof. In particular, the present invention relates to the finding that short peptides derived from the soluble amyloid precursor protein α (sAPPα) bind and modulate GABABR1a. The peptides are provided for clinical use, more particularly for the treatment of neurological diseases such as CMT as well as for psychiatric disorders.

Original language	English
Patent number	WO2023017190
Publication status	Published - 2023

Handle.net

Persistent link

Cite this

@misc{e431be654a4f4ff19dacf24e716fa008,

title = "NOVEL MODULATORS OF GABABR1a",

abstract = "The present invention relates to the field of disorders of the central and peripheral nervous system, in particular neurological and psychiatric disorders, and the prevention and/or treatment thereof. In particular, the present invention relates to the finding that short peptides derived from the soluble amyloid precursor protein α (sAPPα) bind and modulate GABABR1a. The peptides are provided for clinical use, more particularly for the treatment of neurological diseases such as CMT as well as for psychiatric disorders.",

author = "{de Wit}, Joris and Santos, {Ana Rita} and Jo{\~a}o Carvalho and Laurent Galibert and {Van Molle}, Inge and Han Remaut and Sylvain Celanire",

year = "2023",

language = "English",

type = "Patent",

note = "WO2023017190",

}

TY - PAT

T1 - NOVEL MODULATORS OF GABABR1a

AU - de Wit, Joris

AU - Santos, Ana Rita

AU - Carvalho, João

AU - Galibert, Laurent

AU - Van Molle, Inge

AU - Remaut, Han

AU - Celanire, Sylvain

PY - 2023

Y1 - 2023

N2 - The present invention relates to the field of disorders of the central and peripheral nervous system, in particular neurological and psychiatric disorders, and the prevention and/or treatment thereof. In particular, the present invention relates to the finding that short peptides derived from the soluble amyloid precursor protein α (sAPPα) bind and modulate GABABR1a. The peptides are provided for clinical use, more particularly for the treatment of neurological diseases such as CMT as well as for psychiatric disorders.

AB - The present invention relates to the field of disorders of the central and peripheral nervous system, in particular neurological and psychiatric disorders, and the prevention and/or treatment thereof. In particular, the present invention relates to the finding that short peptides derived from the soluble amyloid precursor protein α (sAPPα) bind and modulate GABABR1a. The peptides are provided for clinical use, more particularly for the treatment of neurological diseases such as CMT as well as for psychiatric disorders.

UR - http://v3.espacenet.com/textdoc?DB=EPODOC&IDX=WO2023017190&F=0

M3 - Patent

M1 - WO2023017190

ER -

NOVEL MODULATORS OF GABABR1a

Abstract

Handle.net

Other files and links

Fingerprint

Cite this